Navigation Links
Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease
Date:9/30/2009

CRANBURY, N.J., Sept. 30 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced it plans to initiate a Phase 1 study of AT2220 (1-deoxynojirimycin HCl), its investigational drug in development for the treatment of Pompe Disease. The primary objective of this study is to evaluate the pharmacokinetics of AT2220 in muscle tissue in healthy adult subjects. The U.S. Food and Drug Administration (FDA) has agreed to Amicus' proposal for the Phase 1 study and subsequently converted the clinical hold of AT2220 to a partial hold to allow the conduct of this study.

In June 2008, the Company announced the commencement of a Phase 2 clinical trial of AT2220 in adults with Pompe disease based on data from both preclinical and Phase 1 studies. In February 2009, the Company announced it had suspended enrollment after two patients enrolled in the trial experienced serious adverse events that were probably related to treatment with AT2220. The AT2220 Investigational New Drug application (IND) was subsequently placed on clinical hold by the FDA.

The Company has completed a thorough evaluation of all data from these two subjects and has completed additional preclinical studies of AT2220. Based on these data, the Company proposed the planned Phase 1 study to FDA in order to further evaluate the pharmacokinetics of AT2220 in muscle, the key target tissue in Pompe disease. This study will be an open label, single dose study and will commence in the fourth quarter of this year. The Company expects data from this trial to be available in the first quarter of 2010. Based on the results of this study, the Company will determine the appropriate next steps for the program working in close collaboration with the FDA.

One of the recently completed preclinical studies evaluated the effects of various doses and regimen
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 2015  MT Services LLC, a Lawsuit Settlement ... that U.S. District Judge Joseph Goodwin ... status meeting in hopes to resolve more than ... manufacturers who are involved in multidistrict litigations under ... going on for some time, and Judge Goodwin ...
(Date:4/25/2015)... Join us for a webinar at 12 ... Times using the Transcreener® ADP Assay , Register ... increasingly being incorporated into lead development efforts because longer ... increased therapeutic window and reduced side effects. Though ... such surface plasmon resonance, conjugation of drugs can affect ...
(Date:4/24/2015)... MN , April 24, 2015 /PRNewswire/ - BioAmber ... by Bayer MaterialScience as the supplier of bio-succinic ... innovative, bio-based polyurethanes for textile applications that Bayer ... MaterialScience has launched IMPRANIL ® eco, a ... content that reaches as high as 65%.  IMPRANIL ...
(Date:4/24/2015)... 2015 Seoul Semiconductor announced the ... applications in the lighting market. In recent ... this technology in emerging markets such as Russia, ... range of applications such as streetlight and area ... , First launched in 2005 the Acrich technology ...
Breaking Biology Technology:Transvaginal Mesh Lawsuit News: Another Joint Conference Status Meeting Ordered by Judge to Resolve More than 70K TVM Lawsuits against Several Mesh Manufacturers, Says Lawsuitsettlementnews.com 2Transvaginal Mesh Lawsuit News: Another Joint Conference Status Meeting Ordered by Judge to Resolve More than 70K TVM Lawsuits against Several Mesh Manufacturers, Says Lawsuitsettlementnews.com 3BellBrook Labs Webinar: Analyzing Kinase Inhibitor Residence Times using the Transcreener® ADP Assay 2Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 2Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 3Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 4Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2
... Genome,Sciences, Inc. (Nasdaq: HGSI ) announced today ... Phase 2 clinical trial of HGS-ETR1 (mapatumumab) in,combination ... therapy in patients with advanced non-small cell lung ... newly diagnosed with non-small cell,lung cancer have locally ...
... abuse treatment for teens and adults, HIGHLANDS RANCH, ... the expansion of its treatment services to,include a detox ... 17 as well,as adults, and the hospital has added ... dual diagnosis (substance abuse and,mental illness)., Teen suicide ...
... LifeCell,Corporation (Nasdaq: LIFC ), today announced ... 2008 financial guidance on Monday, January,7, 2008 at ... Executive,Officer, will host a conference call at 10:00 ... revenues and expected financial performance,for 2008., The ...
Cached Biology Technology:Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 2Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 3Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 4Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 5Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 6Highlands Behavioral Health Hospital Unveils New Substance Abuse Detox Program 2LifeCell Corporation Schedules 2008 Financial Guidance Release and Conference Call; January 7, 2008 at 10:00 A.M. Eastern 2
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
(Date:3/20/2015)... 20, 2015 Research and Markets ... the "India Sensors Market Forecast and Opportunities ... The sensor market is projected to grow at ... Consumer electronics, automotive, industrial and healthcare sectors are ... country. In addition, adoption of MEMS technology in ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... wallet is one of the products featured in 2015 ... 20th at 11:00 PM EST on the DIY Network. ... Las Vegas , site of the ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... study sheds new light on the role of carbon dioxide ... that instead of sinking, carbon dioxide is often consumed by ... dimly lit area 100 to 1,000 meters below the surface. ... it can be stored and prevented from re-entering the atmosphere ...
... for understanding life. DNA replication remains difficult to investigate ... double-membrane nucleus. However, the process is far easier to ... 40 (SV40), the large T-antigen protein (T-ag) is responsible ... the origin of replication. SV40 T-ag can also cause ...
... against amyloid-beta, the protein that forms plaques in the ... the brain from damage in early stages of the ... Hospital (MGH) researchers finds that lack of a protein ... led to increased amyloid-beta deposits and earlier death in ...
Cached Biology News:Ocean's 'twilight zone' may be a key to understanding climate change 2Blocking immune cell action increases Alzheimer's-associated protein deposits 2Blocking immune cell action increases Alzheimer's-associated protein deposits 3
...
... 1 Block MBS Start up kit. Includes ... and choice of 1 MultiBlock satellite ... 30 blocks. User friendly software. ... Adjustable height heated lid. Outstanding uniformity. ...
For relative and/or absolute quantification with standard accuracy requirements using MS or NMR instruments...
For testing the AQUA technique on your MS instruments....
Biology Products: